Latest News and Press Releases

Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio.

New York, USA, March 23, 2023 (GLOBE NEWSWIRE) -- Bile Duct Cancer Market to Upsurge at a Significant CAGR by 2032, Assesses DelveInsight The bile duct cancer market is anticipated to surge in the...

Oslo, 28 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug...

Oslo (Norway), 7 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2021 results. Please find enclosed the report and presentation. ...

Oslo (Norway), 6 April 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that...

Oslo (Norway), 26 October 2020 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...

Oslo (Norway), 26 February 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed the...

Pune, June 19, 2019 (GLOBE NEWSWIRE) -- The global Biliary Tumor Market is likely to derive growth from increasing usage approvals in the forthcoming years. According to an upcoming report by...

The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma NEW YORK, Oct. ...